after yesterdays agm statement the share price has risen 50% how much upside is left or is this another false dawn?
http://www.alexa.com/data/details/traffic_details/thewellnessshop.co.uk
womans hour link below.
http://www.bbc.co.uk/radio4/womanshour/04/2008_08_mon.shtml

< strong>Read and enjoy:-)
Institute of Psychiatry - It is most welcome that ACD2 corrects some of ACD1s errors and recommends both FearFighter for panic/phobia and Beating the Blues for depression, so widening the range of sufferers who will have more
choice and be able to access effective help quickly.

Clinical Expert 1 - I am also pleased that Beating the Blues continues to be recommended in 1.1 as an option for the treatment of mild and moderate depression.

Department of Health - We welcome your recommendations on Beating the Blues and Fearfighter.

Clinical Expert 3 - I would recommend the wording be changed slightly to There is insufficient evidence to recommend Cope and Overcoming Depression as cost effective options for the treatment of depression, except as part of ongoing or new clinical trials.etc

Media Innovations - We are quite happy to acknowledge that the evidence
base for Overcoming Depression is not as strong as yet
as for Beating the Blues.

and for balance...NHS Quality Improvement Scotland 2 - It would seem
appropriate to use the Scottish conclusion of Not proven for COPE and Overcoming Depression i.e. to reflect the situation that there is some evidence of
effectiveness, but evidence of efficacy is required through well planned RCT studies.

There are also a lot of comments from the Institute of Psychiatry regarding BTSteps (now called OCFighter). They seem to agree with St Solutions regarding relaxation being an appropriate comparator in RCTs. I strongly suspect that this is the point that they have appealed on (if it is them who has appealed). The DoH also seem to agree...

Department of Health - On OC Fighter I would be grateful if you could clarify and re-examine the view of relaxation as a comparator treatment. OC Fighter is more effective than relaxation but this appears to have been overlooked as evidence of effectiveness. The consultation suggests that it does not view relaxation as an example of usual treatment, even though it is often used in clinical practice.

I think at worst the appeal hearing could result in a slight re-wording of the FAD to make it clearer that COPE and Overcoming Depression should not be dismissed until further RCT evidence is available. However, the recommendation for BtB should be unaffected. All consultees seem to be in agreement that BtB is the most cost-effective and proven method for treatment of moderate/mild depression so I can't see this not being implemented. If further evidence becomes available on the other products then this can be considered when CCBT is reviewed (after 18 months I think - Sept '08). I can't see the current recommendation for BtB being effectively being put on hold just so the other 2 companies can gather further evidence - why wait when the most proven, cost-effective product is ready to roll??

Woody - what's the word on the streets??

ss not long keep the faith

ss sorry forgot to welcome you

taken from nice website Computerised cognitive behaviour therapy (CCBT) for depression and anxiety (review)

Appeal

The Institute has received one appeal against the Final Appraisal Determination and Guidance on this technology. The appeal hearing is currently being arranged.

As set out in the Guidance for Appellants members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. The number of observers admitted to the hearing will be limited to a number appropriate for the venue, and priority will be given to members of the public who are not employed by the appellant. Details of the hearing and how to register to attend will be posted on this page when they have been finalised. The Institute will not accept early requests to attend.

The name of the appellant will be published on this page on the day of the appeal. The Institute will not comment on speculation as to the identity of appellants prior to publication of this information on the Institutes website.

ultrasis have updated their web site,

re appeal dated yesterday.

pbo

here is full copy from website
NICE has nearly completed its very structured due process of the above review. The last phase of the process provides an opportunity for appeal against the final drafting of the report and recommendations. We understand that an appeal has been made but we do not know by whom and on what grounds, NICE will not release any further details until the appeal is heard. A date has not been set for the hearing at this time.

We do not expect that the current draft will change in respect of Beating the Blues. The appeal process will extend the final date for Completion of the process and subsequent recommendation by up to 2 months. Whilst this is frustrating for all of us there is nothing we can do that will change this. The company and NICE has been inundated with calls and emails regarding this matter which is taking up valuable resource. Ultrasis will communicate, any further updates regarding the NICE timescales, via our website.

A 5 star buy confirmed on British Bulls yesterday for ULT.

Nice to have that confirmed by BritishBullshit but in any case we seem to have established strong support at 2p. Positive news from here should move the sp north nicely and I don't think we'll have to wait long for that.

pbo , woodie the web site i have for Ultrasis is http://www.ultrasis.com/news/latest.html
and the news you mention in your posts 221 and 222 i don't see - help please which web site you looking at - many thanks p/271

http://www.ultrasis.com/index.html


pension271, this is the link to ult home page,

the news is on this page at the bottom.

pbo

pbo -thank you - p/271

Thanks Woodie, you've never been wrong before ;)

The Krauts were always keen sellers in the past few months. The past few days they've been buying agressively and are now offering at 3p, way above the rest of the MMs.

Where is this one heading.

Heading up by the looks of it. The market obviously likes the new guy.

ss sorry this was not the rns you expected when i said one would be issued shortly market has taken the news in a positive manner even this news could not get it below 2p

PRESS RELEASE (NICE website, 28/09/05)
Latest NICE guidance sets new standards for
treating depression in children and young people

The National Institute for Health and Clinical Excellence (NICE) and the National
Collaborating Centre for Mental Health have today (28th September) launched a clinical
guideline on the treatment and management of depression in children and young people.
The guideline recommends that
o Children and young people with moderate to severe depression should be offered, as
a first-line treatment, a specific psychological therapy (such as cognitive behavioural
therapy, interpersonal therapy or family therapy of at least 3 months duration).
o Antidepressant medication should not be offered to children or young people with
moderate to severe depression except in combination with a concurrent psychological
therapy and should not be offered at all to children with mild depression.....

...Dr Tim Kendall, Joint Director of the National Collaborating Centre for Mental Health
who developed the guideline on behalf of NICE says This is the sixth mental health
guideline where we have recommended psychological treatments as key treatments for a
mental health condition and the third where we have recommended them as the first line
treatment. The evidence supporting these treatments is robust and it is vital that the NHS
provides psychological therapies to ensure everyone who needs these treatments can
access them rapidly.

Considering the vast majority of young people have access to a computer surely it is just a matter of time before somebody makes the obvious link to the computer based products offered by ULT; this can only strengthen their case.

jk NICE find

This is great endorsement by NICE. Long may it continue. Upwards and onwards